447 related articles for article (PubMed ID: 28244291)
21. Bone marrow transplantation versus prolonged intensive chemotherapy for children with acute lymphoblastic leukemia and an initial bone marrow relapse within 12 months of the completion of primary therapy: Children's Oncology Group study CCG-1941.
Gaynon PS; Harris RE; Altman AJ; Bostrom BC; Breneman JC; Hawks R; Steele D; Zipf T; Stram DO; Villaluna D; Trigg ME
J Clin Oncol; 2006 Jul; 24(19):3150-6. PubMed ID: 16717292
[TBL] [Abstract][Full Text] [Related]
22. Toxicity and efficacy of intensive chemotherapy for children with acute lymphoblastic leukemia (ALL) after first bone marrow or extramedullary relapse.
Thomson B; Park JR; Felgenhauer J; Meshinchi S; Holcenberg J; Geyer JR; Avramis V; Douglas JG; Loken MR; Hawkins DS
Pediatr Blood Cancer; 2004 Oct; 43(5):571-9. PubMed ID: 15382275
[TBL] [Abstract][Full Text] [Related]
23. Bortezomib, Dexamethasone, Mitoxantrone, and Vinorelbine (BDMV): An Active Reinduction Regimen for Children With Relapsed Acute Lymphoblastic Leukemia and Asparaginase Intolerance.
Yeo KK; Gaynon PS; Fu CH; Wayne AS; Sun W
J Pediatr Hematol Oncol; 2016 Jul; 38(5):345-9. PubMed ID: 27352191
[TBL] [Abstract][Full Text] [Related]
24. [Treatment outcome of childhood standard-risk and median-risk acute lymphoblastic leukemia with CCLG-2008 protocol].
Liu X; Zou Y; Wang H; Chen X; Ruan M; Chen Y; Yang W; Guo Y; Liu T; Zhang L; Wang S; Zhang J; Liu F; Cai X; Qi B; Chang L; Zhu X
Zhonghua Er Ke Za Zhi; 2014 Jun; 52(6):449-54. PubMed ID: 25190166
[TBL] [Abstract][Full Text] [Related]
25. Induction-consolidation with an idarubicin-containing regimen, unpurged marrow autograft, and post-graft chemotherapy in adult acute lymphoblastic leukaemia.
Bassan R; Lerede T; Di Bona E; Rambaldi A; Rossi G; Pogliani E; Oriani A; D'Emilio A; Izzi T; Lambertenghi-Deliliers G; Corneo G; Barbui T
Br J Haematol; 1999 Mar; 104(4):755-62. PubMed ID: 10192437
[TBL] [Abstract][Full Text] [Related]
26. Weekly polyethylene glycol conjugated L-asparaginase compared with biweekly dosing produces superior induction remission rates in childhood relapsed acute lymphoblastic leukemia: a Pediatric Oncology Group Study.
Abshire TC; Pollock BH; Billett AL; Bradley P; Buchanan GR
Blood; 2000 Sep; 96(5):1709-15. PubMed ID: 10961868
[TBL] [Abstract][Full Text] [Related]
27. ALL R-87 protocol in the treatment of children with acute lymphoblastic leukaemia in early bone marrow relapse.
Giona F; Testi AM; Rondelli R; Amadori S; Arcese W; Meloni G; Moleti ML; Ceci A; Pillon M; Madon E; Comis M; Pession A; Mandelli F
Br J Haematol; 1997 Dec; 99(3):671-7. PubMed ID: 9401083
[TBL] [Abstract][Full Text] [Related]
28. High-dose cytosine arabinoside and L-asparaginase in refractory acute lymphoblastic leukemia: the Children's Cancer Group experience.
Harris RE; Sather HN; Feig SA
Med Pediatr Oncol; 1998 Apr; 30(4):233-9. PubMed ID: 9473758
[TBL] [Abstract][Full Text] [Related]
29. Outcomes of patients with childhood B-cell precursor acute lymphoblastic leukaemia with late bone marrow relapses: long-term follow-up of the ALLR3 open-label randomised trial.
Parker C; Krishnan S; Hamadeh L; Irving JAE; Kuiper RP; Révész T; Hoogerbrugge P; Hancock J; Sutton R; Moorman AV; Saha V
Lancet Haematol; 2019 Apr; 6(4):e204-e216. PubMed ID: 30826273
[TBL] [Abstract][Full Text] [Related]
30. [Preliminary results of BFM 96 protocol in treatment of childhood ALL relapse in the experience of the Polish Paediatric Leukaemia /Lymphoma Study Group].
Chybicka A; Bogusławska-Jaworska J; Gorczyńska E; Armata J; Balcerska A; Balwierz W; Bubala H; Filiks-Litwin B; Kołecki P; Kowalczyk J; Łukowska K; Matysiak M; Rokicka-Milewska R; Rola-Kurc E; Stencel D; Sonta-Jakimczyk D; Strojny W; Wachowiak J; Wieczorek M; Wysocki M; Zelenay E
Med Wieku Rozwoj; 2000; 4(1 Suppl 2):43-8. PubMed ID: 12021461
[TBL] [Abstract][Full Text] [Related]
31. Survival outcome following isolated central nervous system relapse treated with additional chemotherapy and craniospinal irradiation in childhood acute lymphoblastic leukemia.
Kumar P; Kun LE; Hustu HO; Mulhern RK; Hancock ML; Coffey D; Rivera GK
Int J Radiat Oncol Biol Phys; 1995 Feb; 31(3):477-83. PubMed ID: 7852109
[TBL] [Abstract][Full Text] [Related]
32. A single high dose of idarubicin combined with high-dose ARA-C (MSKCC ALL-3 protocol) in adult and pediatric patients with acute lymphoblastic leukemia. Experience at the University "La Sapienza" of Rome.
Testi AM; Moleti ML; Giona F; Annino L; Chiaretti S; Del Giudice I; Todisco E; D'Elia G; Ferrari A; Arcese W; Mandelli F
Haematologica; 1997; 82(6):664-7. PubMed ID: 9499665
[TBL] [Abstract][Full Text] [Related]
33. Treatment of occult or late overt testicular relapse in children with acute lymphoblastic leukemia: a Pediatric Oncology Group study.
Wofford MM; Smith SD; Shuster JJ; Johnson W; Buchanan GR; Wharam MD; Ritchey AK; Rosen D; Haggard ME; Golembe BL
J Clin Oncol; 1992 Apr; 10(4):624-30. PubMed ID: 1548525
[TBL] [Abstract][Full Text] [Related]
34. Remission Rate of Acute Lymphoblastic Leukemia (ALL) in Adolescents and Young Adults (AYA).
Vallacha A; Haider G; Raja W; Kumar D
J Coll Physicians Surg Pak; 2018 Feb; 28(2):118-121. PubMed ID: 29394970
[TBL] [Abstract][Full Text] [Related]
35. Case-control analysis of allogeneic bone marrow transplantation versus maintenance chemotherapy for relapsed ALL in children.
Hoogerbrugge PM; Gerritsen EJ; vd Does-van den Berg A; vd Berg H; Zwinderman AH; Hermans J; Vossen JM
Bone Marrow Transplant; 1995 Feb; 15(2):255-9. PubMed ID: 7773215
[TBL] [Abstract][Full Text] [Related]
36. Peripheral blast counts at diagnosis of late isolated bone marrow relapse of childhood acute lymphoblastic leukemia predict response to salvage chemotherapy and outcome. Berlin-Frankfurt-Münster Relapse Study Group.
Bührer C; Hartmann R; Fengler R; Rath B; Schrappe M; Janka-Schaub G; Henze G
J Clin Oncol; 1996 Oct; 14(10):2812-7. PubMed ID: 8874343
[TBL] [Abstract][Full Text] [Related]
37. High cure rate with a moderately intensive treatment regimen in non-high-risk childhood acute lymphoblastic leukemia. Results of protocol ALL VI from the Dutch Childhood Leukemia Study Group.
Veerman AJ; Hählen K; Kamps WA; Van Leeuwen EF; De Vaan GA; Solbu G; Suciu S; Van Wering ER; Van der Does-Van der Berg A
J Clin Oncol; 1996 Mar; 14(3):911-8. PubMed ID: 8622039
[TBL] [Abstract][Full Text] [Related]
38. Outcome of adult acute lymphoblastic leukemia with BFM protocol in a resource-constrained setting.
Malhotra P; Varma S; Varma N; Kumari S; Das R; Jain S; Ahluwalia J; Mahi S; Sharma SC; Radhika S
Leuk Lymphoma; 2007 Jun; 48(6):1173-8. PubMed ID: 17577781
[TBL] [Abstract][Full Text] [Related]
39. Fractionated cyclophosphamide added to the IVAP regimen (idarubicin-vincristine-L-asparaginase-prednisone) could lower the risk of primary refractory disease in T-lineage but not B-lineage acute lymphoblastic leukemia: first results from a phase II clinical study.
Bassan R; Pogliani E; Lerede T; Fabris P; Rossi G; Morandi S; Casula P; Lambertenghi-Deliliers G; Vespignani M; Izzi T; Coser P; Corneo G; Barbui T
Haematologica; 1999 Dec; 84(12):1088-93. PubMed ID: 10586210
[TBL] [Abstract][Full Text] [Related]
40. FLAG-IDA in the treatment of refractory/relapsed acute leukaemias: single centre study.
Hashmi KU; Khan B; Ahmed P; Raza S; Hussain I; Mahmood A; Iqbal H; Malik HS; Anwar M
J Pak Med Assoc; 2005 Jun; 55(6):234-8. PubMed ID: 16045091
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
